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Abstract
Background and aims: Congenital hypothyroidism (CH) is one of the most common treatable physical growth disorders leading to mental 
retardation. Most cases of this disease can be detected through the neonatal screening program. Given the high prevalence of this disease 
and the implementation of screening programs in recent years in Iran, this study aimed to assess the growth indices of newborns with CH.
Methods: In this retrospective cohort study, 66 newborns with CH detected in the screening program in Shahrekord were selected by a 
census sampling method. Overall, 125 healthy newborns were also selected as controls by the convenience sampling technique according 
to the inclusion and exclusion criteria. The height, weight, head circumference, and body mass index (BMI) of the samples were measured 
and then the mean, median, standard deviation, as well as the 3rd, 15th, 25th, 50th, 75th, 85th, and 97th percentiles in the two groups were 
determined and compared based on gender and age group.
Results: The height, weight, head circumference, and BMI of the boys, in addition to the head circumference and BMI of the girls, were not 
significantly different from those of the controls (P > 0.05). However, the height and weight of the girls were significantly lower compared 
to those in the control group, although the difference in the weight was corrected at the age of 9 months.
Conclusion: In general, the growth indices of newborns with CH were lower than those of the controls. This difference was significant only 
for the weight and height of girls with CH. 
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Introduction 
The growth of fetuses and children depends on the function 
of certain hormones, the most important of which are 
thyroid and growth hormones (1). Hypothyroidism in 
newborns is caused by the deficiency of thyroid hormone in 
fetuses, neonates, and infants and refers to the underactive 
thyroid gland, which exists before or at birth (2). Congenital 
hypothyroidism (CH) is considered as one of the most 
common diseases involving endocrine glands in children 
and one of the preventable causes of mental retardation 
(3). This disease is twice as prevalent in girls as in boys (4). 
In the United States, the prevalence of hypothyroidism 
increases 3% per year and the deficiency of iodine is still 
the main cause of the prevalence of this disease worldwide 
(5). Most newborns with CH do not present with the 
symptoms of the disease at birth. However, some studies 
indicate that delayed diagnosis and disease treatment 
lead to irreversible mental retardation, misaligned eyes, 
learning difficulties, neurological complications, severe 
physical growth problems, short stature, and the like 
(5-7). Oral levothyroxine is the treatment of choice for 
the disease (4). In Asian countries, especially Iran, the 
prevalence of CH is higher than the worldwide standard 
due to consanguineous marriage, iodine deficiency, and 
genetics (8). The incidence rate of this disease in Iran is 
1/400 to 1/900 live births (9). The worldwide incidence 
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of this disease is 1/2000 to 1/4000 live births. Therefore, 
the screening program of hypothyroidism in newborns 
started in 1970. Nowadays, it is implemented in most 
industrialized and developing countries (10,11). Azizi 
et al. first implemented the screening program of CH in 
some provinces of Iran in 1987 (12). The implementation 
of the screening program, along with the early diagnosis 
and immediate treatment of the affected newborns, leads 
to the normalization of their growth and cognitive and 
intellectual functionality (13). 
Screening is conducted to detect, control, and manage 
the treatment of the affected newborns at birth, as well as to 
detect the transient cases of the disease (3). Screening, along 
with early diagnosis and treatment, leads to normal body 
and brain growth in addition to the normal intellectual 
and cognitive functionality of newborns with CH (5). 
Hypothyroidism is caused by a deficiency of the thyroid 
hormone production or the thyroid gland, or thyroid-
stimulating hormone (TSH) deficiency. The biochemical 
diagnosis must be made immediately after birth (4). The 
conventional newborn screening was carried out in all 
the states of the United States to measure the amount of 
TSH in samples collected from the umbilical cord or the 
heel stick. To this end, a serum sample was immediately 
collected from each newborn with a positive screening test 
in order to confirm low T4 and high TSH (14). According 
to national guidelines, the newborn was followed up 2 and 
4 weeks after treatment, every 2 months during the first 6 
months, every 3 months within the ages of 6-36 months, 
and if the child develops permanent CH, every 6 months 
after the age of 36 months (12).
Body mass index (BMI) is a recommended screening tool 
for children and adolescents (14). One study showed that 
head circumference was higher in children with CH than 
the normal range (15). Various studies have investigated 
the developmental pattern of CH children worldwide and 
the results showed some differences between the growth 
indices of these children and healthy individuals. Some 
of these studies suggested that these children have growth 
retardation compared to others or their growth is less than 
that of the other normal children (16-25).
The implementation of the screening program for CH 
in accordance with national guidelines was successfully 
implemented in Chaharmahal va Bakhtiari province so 
that 80% of healthcare centers conducted the program 
satisfactorily (26). 
However, no study has so far focused on this health issue 
in this province and no comprehensive assessment has 
yet been carried out on the linear growth and the BMI of 
children with CH. Therefore, this study aimed to analyze 
the growth process of children with CH in order to assess 
the effectiveness of early treatment initiation. For this 
purpose, the growth indices such as weight, height, head 
circumference, and the BMI of children with CH taking 
levothyroxine and those without CH were compared to 
determine the effectiveness of the CH screening program.
Materials and Methods
In this retrospective cohort study that was conducted in 
2014, children diagnosed with CH during the newborn 
screening program in Shahrekord during 2006-2013 
comprised the study population. To select the samples for 
the treatment group, sampling was conducted by census, 
while the controls were selected by the convenience 
sampling method from among the relatives or neighbors of 
the samples in the treatment group who were matched for 
residence place, age, and gender with the treatment group. 
During the newborn screening program implemented in 
Shahrekord between 2006 and 2013, 102 children were 
diagnosed with the disease. According to the inclusion and 
exclusion criteria, 66 children diagnosed with the disease 
and 125 healthy children were assigned to the treatment 
and control groups, respectively. The exclusion criteria 
were the presence of a simultaneous disease, malnutrition, 
prematurity (giving birth before the 37th week of 
gestation), intrauterine growth restriction and small for 
the gestational age, and children with genetic problems 
like Down syndrome or severe anomalies. After obtaining 
the parents’ consent forms and assuring the confidentiality 
and lack of imposing costs, the necessary approvals of the 
Provincial Health Center and the information about the 
growth indices of children from birth to 5 years of age were 
collected from the health care centers. 
The collected information included height (cm), weight 
(g), head circumference (cm, in children under 2 years of 
age), and BMI (kg/m², in children aged 2 years and over). 
The mean, median, standard deviation, and the 3rd, 15th, 
25th, 50th, 75th, 85th, and 97th percentiles were calculated 
based on age and gender in both the treatment and control 
groups and compared in order to describe the data. Finally, 
descriptive and inferential statistics (t test) in the SPSS were 
used for data analysis.
Results
Out of the 66 children with CH in the treatment group, 
41 (62.1%) cases were boys and 25 (37.9%) of them were 
girls. From among 125 children in the control group, 
65 (52%) and 60 (48%) of them were boys and girls, 
respectively. No significant difference was observed in 
the mean height and weight between boys with CH and 
healthy boys in all age groups (P > 0.05). Although height 
and weight were lower in boys with CH in almost all age 
groups compared to healthy boys, the height of the girls 
with CH was significantly lower than that of healthy girls 
in all age groups except for birth height at 1 and 3 years 
of age. The weight of the girls with CH was significantly 
lower than that of healthy girls at 2, 3, 4, and 6 months of 
age (P < 0.05), the details of which are provided in Table 1.
Although the head circumference and BMI of healthy 
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boys were higher than those of boys with CH, no significant 
difference was observed in any of the age groups. Further, 
no significant difference was found in head circumference 
and BMI between healthy girls and girls with CH in almost 
all age groups (P > 0.05), data of which are presented in 
Table 2.
The mean TSH of newborns with CH at birth and 3 
years of age was greater than 5, while it was lower than 5 in 
other age groups. In children with CH, the T4 levels were 
almost normal in all age groups except for children at birth 
(Table 3).
The comparison of height percentiles in boys revealed 
that the height was almost higher in healthy boys at the 
percentiles of 3, 15, and 25 compared to boys with CH 
in different age groups. At the percentile of 50, height was 
almost higher in healthy children compared to children 
with CH except for 4 months old and at the percentile of 
75 except for 3 months old.
At the percentile of 85, in newborns at birth and 2, 3, 
and 6 months and 4 years of age, the height was almost 
higher in children with CH compared to healthy children. 
At the percentile of 97, at 2 and 4 months, as well as 2, 4, 
and 5 years of age, the height was almost higher in children 
with CH compared to healthy children. In general, a small 
difference in height was observed between the two groups 
at higher percentiles.
Furthermore, the height was higher in healthy girls at the 
percentile of 3 compared to girls with CH in all age groups 
except for 3, 4, and 5 years of age. At other percentiles, 
the height was higher in healthy girls when compared with 
those girls with CH in all age groups (Figure 1).
At the percentile of 3, the weight at the age of 2 months 
was higher in newborns with CH as compared to healthy 
newborns. However, the weight became higher in healthy 
children after 2 months of age. At percentiles of 15 and 
25, the weight of healthy children was higher than that of 
children with CH in all age groups. 
Moreover, the weight was higher in children with CH 
at the percentile of 50 at birth in addition to 4, 6, 9, and 
12 months of age when compared to healthy children, 
while it was lower in children with CH in the other age 
groups. Additionally, the results revealed that the weight 
was higher in children with CH at the percentile of 75 at 
birth, 2 months, as well as 1.5, 3, 4, and 5 years of age 
Table 1. The comparison of height and weight in girls and boys with and without congenital hypothyroidism 
Age Sex
Height (cm) Weight (g)
Healthy With CH P value Healthy With CH P value
0
Girls 49.45 ± 2.03 49.15 ± 2.13 0.55 3057.83 ± 440.70 3010 ± 548.80 0.67
Boys 49.46 ± 2.03 49.04 ± 3.07 0.39 3460.30 ± 3197.44 3134.87 ± 532.82 0.52
2 months
Girls 57.46 ± 2.56 56.12 ± 3.41 0.05* 5075.47 ± 534.98 4522 ± 605.54 0.000*
Boys 57.54 ± 2.56 57.10 ± 3.14 0.44 5312.90 ± 743.38 5224.39 ± 977.76 0.60
3 months
Girls 60.09 ± 2.57 58.60 ± 3.19 0.03* 5765.38 ± 41667 5375 ± 660.36 0.02*
Boys 60.81 ± 2.54 63.27 ± 3.02 0.33 6056.66 ± 687.26 5943.75 ± 903.63 0.46
4 months
Girls 62.82 ± 2.57 61.16 ± 2.70 0.01* 6424.54 ± 777.57 5892 ± 693.97 0.004*
Boys 63.62 ± 2.67 63.46 ± 2.90 0.76 6867.74 ± 806.68 6670.73 ± 977.49 0.26
6 months
Girls 66.47 ± 2.50 64.45 ± 2.46 0.002* 7425 ± 992.06 6881.81 ± 805.71 0.02*
Boys 68.04 ± 4.47 67.11 ± 2.99 0.25 7693.43 ± 862.59 7656.41 ± 1014.25 0.84
9 months
Girls 70.92 ± 2.60 69.44 ± 3.33 0.05* 8403.63 ± 1123.76 7865.78 ± 904.62 0.06
Boys 72.32 ± 3.17 71.25 ± 3.21 0.11 8698.36 ± 1022.29 8562.50 ± 1132.40 0.54
1 year
Girls 75.23 ± 3.81 73.82 ± 3.43 0.07 9211.11 ± 1174.27 8180 ± 2016.66 0.08
Boys 76.12 ± 3.67 75 ± 3.07 0.13 9643.44 ± 1218.45 9276.47 ± 1140.65 0.29
1.5 years
Girls 81.26 ± 3.16 79.23 ± 3.63 0.03* 10445.92 ± 1296.94 9876.47 ± 1205.99 0.11
Boys 82.57 ± 3.88 81.12 ± 3.36 0.07 10841.53 ± 1434.46 10489.39 ± 1280.97 0.24
2 years
Girls 86.63 ± 3.67 83.75 ± 3.82 0.01* 11566.30 ± 1445.03 10935.71 ± 1334.51 0.15
Boys 86.99 ± 4.02 86.13 ± 4.19 0.36 12286.79 ± 2276.47 11541.67 ± 1417.14 0.10
3 years
Girls 95.05 ± 5.65 92.69 ± 5.52 0.20 13523.53 ± 1701.16 12866.67 ± 1613.20 0.25
Boys 95.04 ± 4.51 93.63 ± 5.08 0.37 13708.54 ± 1634.62 13396 ± 184062 0.47
4 years
Girls 104.63 ± 5.05 100.42 ± 2.22 0.04* 15743.48 ± 2447.04 14728.57 ± 1717.27 0.31
Boys 101.24 ± 4.23 99.85 ± 6.36 0.36 15835.48 ± 2190.66 1540 ± 2961.24 0,59
5 years
Girls 113.32 ± 4.70 106.50 ± 1.73 0.01* 18617.65 ± 2788.19 16250 ± 2061.55 0.12
Boys 110.10 ± 4.37 107.26 ± 8.17 0.20 17711.11 ± 2743.52 18073.33 ± 4673.09 0.78
Note. *Significant difference at the level of P<0.05; CH: Congenital hypothyroidism.
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Table 2. The comparison of BMI and head circumference for age in both girls and boys with and without congenital hypothyroidism
Variable Age Sex Healthy With CH P value
Head circumference
 (cm)
0
Girls 34.49 ± 1.30 34.18 ± 2.00 0.41
Boys 34.91 ± 1.33 34.68 ± 1.42 0.39
2 months
Girls 38.62 ± 1.18 37.37 ± 2.83 0.008*
Boys 39.19 ± 1.17 38.51 ± 1.61 0.053
3 months
Girls 39.70 ± 1.15 39.10 ± 1.86 0.09
Boys 40.50 ± 1.19 40.02 ± 1.57 0.08
4 months
Girls 40.78 ± 1.05 40.20 ± 1.56 0.05*
Boys 41.77 ± 1.35 41.32 ± 1.35 0.09
6 months
Girls 42.51 ± 1.19 42.09 ± 1.45 0.18
Boys 43.65 ± 1.30 43.09 ± 1.50 0.052
9 months
Girls 44.34 ± 1.31 43.91 ± 1.27 0.21
Boys 45.32 ± 1.27 44.81 ± 1.76 0.10
1 year
Girls 45.61 ± 1.24 45.11 ± 0.95 0.11
Boys 46.41 ± 1.15 46.14 ± 1.64 0.36
1.5 years
Girls 47.04 ± 1.45 46.58 ± 1.17 0.25
Boys 47.29 ± 1.25 47.79 ± 1.92 0.53
BMI
2 years
Girls 15.40 ± 1.65 15.63 ± 0.99 0.62
Boys 16.27 ± 2.29 15.53 ± 1.04 0.10
3 years
Girls 14.82 ± 1.21 15.36 ± 1.54 0.22
Boys 15.30 ± 1.34 15.24 ± 1.12 0.83
4 years
Girls 14.42 ± 1.74 14.60 ± 1.56 0.81
Boys 15.26 ± 1.44 15.29 ± 1.66 0.77
5 years
Girls 14.58 ± 1.55 14.35 ± 1.53 0.79
Boys 14.53 ± 1.61 15.48 ± 2.19 0.16
Note. *Significant difference at the level of P<0.05; BMI: Body mass index; CH: Congenital hypothyroidism.
Table 3. Thyroid-stimulating hormone and T4 in girls and boys with congenital hypothyroidism
Age
T4 TSH
Girls Boys Girls Boys
0 79.47 ± 38.03 86.04 ± 18.31 42.16 ± 33.40 20.39 ± 13.44
2 months 161.98 ± 49.03 137.39 ± 45.76 3.84 ± 5.30 3.534.58
3 months 120.51 ± 39.68 122.47 ± 20.34 7.47 ± 11.98 2.68 ± 2.76
4 months 145.01 ± 54.13 130.20 ± 28.53 0.66 ± 1.21 1.20 ± 2.16
6 months 109.53 ± 13.42 125.61 ± 25.22 2.97 ± 5.38 2.70 ± 3.10
9 months 121.24 ± 38.72 110.23 ± 14.44 1.30 ± 1.32 1.91 ± 1.64
1 year 101.21 ± 15.21 105.39 ± 10.23 3.22 ± 3.22 2.26 ± 1.37
1.5 years 110.55 ± 21.36 121.37 ± 23.81 2.06 ± 1.68 3.07 ± 1.65
2 years 112.1 ± 16.2 106.28 ± 13.45 2.38 ± 1.079 2.73 ± 2.41
3 years 131.28 ± 34.40 112.47 ± 34.79 1.09 ± 1.06 2.80 ± 1.68
4 years 107 ± 19.7 131.1 ± 28.13 1.20 ± 1.8 2.81 ± 0.83
5 years 114.3 ± 20.2 127.38 ± 26.23 3 ± 1.9 4.91 ± 3.21
Note. TSH: Thyroid stimulating hormone. 
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compared to healthy children. Based on the results, the 
weight was higher in children with CH at the percentile of 
85 at birth and 4 years of age in comparison with healthy 
children, while it was lower in the other age groups. Finally, 
the weight was higher in children with CH at the percentile 
of 97 at 2, 3, 4, 6, and 9 months, along with 4 and 5 years 
of age when compared to healthy children. In general, the 
weight was higher in boys with CH at high percentiles as 
compared to healthy children (Figure 2).
The head circumference at all percentiles and age groups 
was higher in healthy boys compared to boys with CH and 
the difference between the two groups was smaller at higher 
percentiles (Figure 3). 
In addition, the head circumference was higher in 
healthy girls when compared to girls with CH. There were 
some exceptions regarding the head circumference at the 
percentile of 3 at 1 year and 1.5 years of age, at the percentile 
of 25 at 6 months of age, at the percentile of 50 at birth, 
at the percentile of 85 at birth and 6 months of age, and at 
the percentile of 97 at 3 months of age, which were higher 
in children with CH in comparison with healthy children.
The results further demonstrated that the BMI was 
higher in healthy boys at the percentile of 3 as compared 
to boys with CH in all age groups. At this percentile, the 
BMI was higher in girls with CH compared to their healthy 
counterparts in all age groups. At other percentiles, there 
was no specific order between the BMI of healthy children 
and those with CH in different age groups (Figure 4).
Discussion
This study comparatively assessed the growth indices of 
children with CH, who were diagnosed in the screening 
program and underwent levothyroxine treatment, and 
healthy children by the age of 5. According to the findings 
of this study, the height, weight, head circumference, 
and BMI of healthy children and children with CH were 
comparable and no significant difference was observed 
between these two groups. The head circumference and 
BMI of girls with CH and healthy girls were not significantly 
different, while the height and weight of girls with CH and 
healthy girls represented a significant difference. Regarding 
the weight of girls with CH, the difference was adjusted 
over time at the age of 9 months. Overall, the number 
of children with normal height, weight, BMI, and near 
normal head circumference can be increased through the 
timely diagnosis and treatment of children with CH in the 
studied area.
Various studies have shown that the growth pattern of 
children becomes normal through early treatment (17). 
The findings of the study by Grant on 472 children with 
CH in a period of 2 years demonstrated that the growth 
pattern became normal through early treatment (22). In 
the newborn screening program in Barcelona, no difference 
was reported in height, weight, and BMI between children 
with CH and the general population (23). 
In another study, Sato et al evaluated the height, weight, 
and head circumference of 2341 children with CH and 
found that these children have similar growth to that of 
normal children (25). In one study in China, the height, 
weight, and BMI of children with CH from birth to 12 
years of age were assessed and compared to those of the 
healthy children and the findings revealed that the height 
growth of the two groups was similar (27).
The findings of this study and the previous studies 
indicated that growth in children with CH becomes similar 
to that of healthy children through early treatment. In this 
study, the observed difference between girls with CH and 
healthy girls regarding height and weight may be due to the 
difference in levothyroxine dosage between girls and boys or 
unsatisfactory adherence, treatment measures, and follow-
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Figure 1. Height for age percentiles for both genders with and without congenital hypothyroidism.
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Fig2. Weight for age percentiles for both sexes with CH and without CH 
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Figure 3. Head circumference for age percentiles for both genders with and without congenital hypothyroidism
Figure 4. Body mass index for age percentiles for both genders with and without congenital hypothyroidism.
Fig 4. BMI for age percentiles for both sexes with CH and without CH 
 
 
 
 
0
5
10
15
20
25
30
35
2y 3y 4y 5y 2y 3y 4y 5y 2y 3y 4y 5y 2y 3y 4y 5y 2y 3y 4y 5y 2y 3y 4y 5y 2y 3y 4y 5y
Boys with CH Healthy boys Girls with CH Healthy girls
3rd 5th 25th 50th 75th 85th 97th 
                                                              Journal of Shahrekord University of Medical Sciences, Volume 22, Issue 1, 2020 35
Growth parameters of children with congenital hypothyroidism
ups in girls. Aronson et al observed growth restriction in 
children with CH during the first year of life (20), which 
is inconsistent with the results of the above-cited studies. 
The findings of several studies have highlighted growth 
restriction in children with CH (21,28,29). In the study 
of Feizi et al, the specific growth indices in children with 
CH detected in the newborn screening program were 
assessed, indicating that the growth indices of children with 
CH were different from those of the healthy children (7). 
However, these differences were less pronounced at higher 
percentiles and the height, weight, head circumference, and 
BMI of children with CH became closer to those of the 
healthy children and therefore the difference became less 
pronounced by increasing age. This phenomenon occurs 
sooner for weight and later for head circumference (7). 
Regarding height, no significant difference was observed 
between boys with CH and healthy boys, although the 
height of females with CH was significantly lower than 
that of the healthy girls. Although in some studies no 
difference was reported in height growth in children 
with CH (15,25,27,29),  the height at the age of 5 years 
became normal in the study of Feizi et al. Based on the 
findings of Moschini et al, the normal height growth of 
children occurred at 6 years of age and their mean age was 
33 days at the beginning of treatment (21). In our study, 
the height of girls would become close to the normal value 
in subsequent follow-up sessions if any. In another study 
conducted in Liverpool, the height and head circumference 
of children with CH were assessed at 3 years of age and 
the findings revealed that the height in all children with 
CH was within a normal range and no growth disorder was 
observed regardless of the type and causes of the disease 
(15). The findings of a similar study conducted in Italy on 
the height growth, puberty, and final height of children 
with CH represented that the final height in all subjects 
with different etiologies of the disease was within a normal 
range (29). As regards weight, no significant difference was 
found between boys with CH and healthy ones. However, 
a difference in the weight of girls with CH was reported 
by the age of 9 months that was adjusted at higher ages. 
Feizi et al reported that weight in children did not reach the 
expected values by the age of 5 years but tended to indicate 
an increase (7). Sato et al indicated that children with CH 
had normal weight (25). Another research reported weight 
gain (29). The main cause of the observed weight gain in 
previous studies seems to be the inappropriate treatment 
or inadequate cooperation of parents during the treatment. 
As already argued, this observation could be unrelated to 
the linear growth of children afflicted with the disease (30). 
The head circumference up to the age of 1.5 years was lower 
in children with CH than in healthy children, although the 
difference was not statistically significant. In the study of 
Feizi et al, the head circumference of children with CH was 
lower than the normal value, while it became normal at 
the age of 3 years (7). However, this index was higher than 
normal in another study (15). This inconsistency may be 
due to the etiological differences of the disease in different 
countries (31). In Iran, the prevalence of the disease is higher 
than the worldwide standard. In our studied region, ethnic 
and racial differences exist and consanguineous marriage is 
common. Unlike the other regions, dyshormonogenesis is 
considered as the main cause of the disease in this region 
(32). In dyshormonogenesis, the hormones may first seem 
normal but then change to a hormone disorder. In a study 
in Qatar, 45 children with permanent CH were compared 
to the healthy children of the same age and no significant 
difference was reported in head circumference at birth and 
mean weight. In addition, the mean height of children with 
CH at the age of 5 years was significantly low compared 
to that of the children of the same age. The screening 
program accompanied with treatment led to the normal 
linear growth and appropriate mental development of the 
affected children (28).
Similarly, Lotfi et al found that the abnormal growth 
of height, weight, and head circumference was downward 
and no significant difference was reported in the growth 
disorders of the height, weight, and head circumference of 
children with CH and healthy children at the completion 
of 5 years according to the World Health Organization 
(WHO) standards (18).
Some studies investigated the growth indices of children 
with CH undergoing the treatment in accordance with the 
WHO standards (7,18). The present study comparatively 
investigated the height, weight, head circumference, and 
BMI of children with CH and healthy children from the 
same region. The data related to the comparison of the 
growth indices of children with CH and healthy children 
from the same region were compared and more reliable 
results were obtained accordingly. The findings of this 
study are consistent with those of studies conducted in 
Barcelona, Spain (23), and China (27), in which children 
with CH were compared with healthy controls from the 
same region. In a study conducted in the northwest of 
Iran, no significant difference was observed between the 
mean weight of children with CH and that of the healthy 
children at the age of beginning primary education, but the 
mean height of children with CH was significantly lower 
than that of the healthy children. On the other hand, the 
mean head circumference of children with CH at birth was 
slightly higher than that of the healthy children, although 
the difference was not statistically significant (33).
In this study, the BMI was assessed in children from the 
age of 2 years and no significant difference was observed 
between children with CH and healthy children among 
both girls and boys. In the study of Feizi et al, the BMI of 
the treatment group was lower than the expected values, 
which may be due to the impact of weight (7). In one study 
conducted in Greece, it was found that the BMI of children 
with CH in early childhood tends to become normal at 
the beginning of adolescence and the expected variations 
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of BMI during the first year of life in these children are not 
noticeable (24).
In this study, the reason for the high percentage of 
transient hypothyroidism in screening tests can be explained 
by low birth weight newborns and the mothers’ use of 
certain treatments like those for asthma and disinfectants 
containing iodine before giving birth and undergoing 
caesarean section. However, this issue deserves further 
investigation.
Nonetheless, having knowledge about transient CH, 
either iatrogenic or non-iatrogenic, is effective in identifying 
the actual prevalence of permanent hypothyroidism, 
avoiding the excessive drug consumption, and seeking the 
family acceptance of permanent treatment.
Abnormal growth may be considered as a symptom of 
a chronic disease, malnutrition, or developmental and 
mental problems. Children suffering from severe and 
chronic communicable and non-communicable diseases are 
more predisposed to growth disorders compared to other 
children (34). Further, newborns with CH have normal 
appearance and develop few and nonspecific symptoms at 
birth. Therefore, to prevent the effects of hypothyroidism, 
it is recommended not to wait for its symptoms (35). The 
complications of CH may be prevented to a great extent 
through conducting the screening program and early 
diagnosis and treatment. The limitations of our study 
include the migration of some participants and the lack of 
access to some of their information, along with the lack of 
timely referral of some clients to health care centers based 
on the predetermined scheme regarding the assessment of 
their growth indices. 
Conclusion
In this study, the height, weight, head circumference, 
and BMI of boys, as well as the head circumference and 
BMI of girls, were not significantly different from those 
of healthy controls, while the height and weight of girls 
were significantly different from those of healthy controls. 
However, the difference in weight was adjusted at the 
age of 9 months. In general, it can be argued that early 
diagnosis and treatment of newborns with CH will lead to 
the corrections of their growth indices. It is obvious that 
the age at the beginning of the treatment, the severity of 
the disease, and the dosage of the drug can contribute to 
differences between healthy and affected children. 
Accordingly, future studies are recommended to assess the 
effects of age at the beginning of the treatment, as to by 
considering first medicine dosage and then the severity 
of the disease on the growth process of children, and 
subsequently compare the effective dosage of levothyroxine 
in boys and girls.
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